Allegations of Fraud and Corruption Loom Over State-Owned Enterprises' Stocks

May 24, 2024, 10.25 PM | Reporter: Pulina Nityakanti

ILUSTRASI. Penjualan Indofarma tumbuh. Suasana di pabrik farmasi PT Indofarma Tbk (INAF) di Cibitung, Jawa Barat (10/4). Saat ini kapasitas produksi berjalan 100 persen meliputi 2,3 milyar tablet serta 250 juta kapsul pertahun. Indofarma akan melakukan investasi sebesar Rp 100 miliar untuk pengembangan produksi generik dan herbal, serta pemenuhan kebutuhan bahan baku yang saat ini sekitar 90 persen masih impor. Pada triwulan pertama tahun 2012 pabrik farmasi ini tumbuh 50 persen dari triwulan 2011 yakni sekitar Rp 111 miliar. KONTAN/Muradi/10/04/2012

- JAKARTA. A wave of negative news is currently sweeping over the stocks of state-owned enterprises (SOEs) in Indonesia. Not only are these companies grappling with financial issues and high debt burdens, but allegations of corruption and fraud are also surfacing. This could potentially erode investor confidence in these red-plate issuers.

Take PT Indofarma Tbk (INAF), for instance, which is currently haunted by financial troubles leading to a Postponement of Debt Payment Obligations (PKPU). There are also allegations of fraud that have caused losses to the state. INAF has confirmed reports that it has not paid wages or salaries to its employees for the period of March 2024.

Thanks for reading Kontan English.

Please create account or log in.

Only Rp5,000 to continue reading.

BUY NOW!

Editor: Syamsul Azhar